Hematology/ Oncology and Stem Cell Therapy最新文献

筛选
英文 中文
Outcome of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation as a Treatment Option in Patients With Severe Aplastic Anemia Between 40 and 50 Years. 外周血异体造血干细胞移植作为40 - 50岁严重再生障碍性贫血患者的治疗选择的结果
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2020.06.004
Hosein Kamranzadeh Fumani, Mahdi Jalili, Soroush Rad, Davood Babakhani, Nasrollah Maleki, Seyed Asadollah Mousavi, Ardeshir Ghavamzadeh
{"title":"Outcome of Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation as a Treatment Option in Patients With Severe Aplastic Anemia Between 40 and 50 Years.","authors":"Hosein Kamranzadeh Fumani,&nbsp;Mahdi Jalili,&nbsp;Soroush Rad,&nbsp;Davood Babakhani,&nbsp;Nasrollah Maleki,&nbsp;Seyed Asadollah Mousavi,&nbsp;Ardeshir Ghavamzadeh","doi":"10.1016/j.hemonc.2020.06.004","DOIUrl":"https://doi.org/10.1016/j.hemonc.2020.06.004","url":null,"abstract":"<p><p>The frontline treatment for patients younger than 40 years with severe aplastic anemia (AA) is allogeneic hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen-identical sibling donor. However, in patients with severe AA who are older than 40 years, allogeneic HSCT has been found to be associated with increased treatment-related mortality and toxicity, even when matched sibling donors are used. We report our institutional experience with allogeneic HSCT in patients with severe AA between 40 and 50 years. A total of 19 patients with severe AA were included in the study. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method. The mean age of patients at the time of transplant was 43.79 years, and 57.9% were male. The mortality rate was 36.8%, attributed to infection (10.5%), relapse (15.8%), and renal failure (5.3%) in all cases. Acute graft-versus-host disease (GVHD) occurred in five patients (26.3%), and chronic GVHD occurred in two patients (10.5%). The 5-year OS was 62% and the 5-year DFS was 52%. We found that the patient's age, platelet level prior to transplantation, and the number of CD3 cells infused for each transplant were independent prognostic factors for OS, and the age and sex of the patient, graft rejection, and platelet level prior to transplantation were significant prognostic factors associated with DFS. We recommend that immunosuppressive therapy be considered as a first-line treatment in patients with severe AA who are older than 40 years. Allogeneic HSCT can be considered a valid alternative option in patients whose suppression therapy fails.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":" ","pages":"52-58"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.06.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38141354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy: A Case of Lethal Toxicity but Pathological Complete Response in Metastatic Lung Adenocarcinoma. 单周期抗pd -1治疗后致死性自身免疫风暴:转移性肺腺癌致死性毒性但病理完全缓解的一例
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2020.04.006
Jesús Fuentes-Antrás, Paloma Peinado, Kissy Guevara-Hoyer, Cristina Díaz Del Arco, Silvia Sánchez-Ramón, Carlos Aguado
{"title":"Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy: A Case of Lethal Toxicity but Pathological Complete Response in Metastatic Lung Adenocarcinoma.","authors":"Jesús Fuentes-Antrás,&nbsp;Paloma Peinado,&nbsp;Kissy Guevara-Hoyer,&nbsp;Cristina Díaz Del Arco,&nbsp;Silvia Sánchez-Ramón,&nbsp;Carlos Aguado","doi":"10.1016/j.hemonc.2020.04.006","DOIUrl":"https://doi.org/10.1016/j.hemonc.2020.04.006","url":null,"abstract":"<p><p>As immunotherapy agents are incorporated into the routine oncological practice, the number of patients at the risk of immune-related adverse events has increased dramatically. However, the prompt identification and effective management of severe autoimmune complications remain a challenge. We report the case of a patient with metastatic lung adenocarcinoma who experienced a fatal autoimmune storm 3 weeks after the first dose of anti-programmed death receptor-1 (PD-1) agent pembrolizumab, which included thyroiditis, hepatitis, myositis, myocarditis, pneumonitis, and myasthenia gravis. Aggressive autoimmunity was supported by extensive T-cell and macrophage tissue infiltrates and autoantibody positivity. Remarkably, no residual tumor was found at autopsy. This case illustrates the potential harm caused by immunotherapy and our limited knowledge on its prevention, treatment, and association to antitumor efficacy.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":" ","pages":"63-67"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.04.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37964105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Recurrence Score Testing Does not Appear to Benefit Patients With Grade 1, Progesterone Receptor-Positive Breast Cancers: An Opportunity to Eliminate Overtreatment and Decrease Testing Costs. 复发评分测试似乎不能使1级孕激素受体阳性乳腺癌患者受益:消除过度治疗和降低测试成本的机会。
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2021.05.005
Udai S Sibia, Thomas J Sanders, Charles Mylander, Martin Rosman, Carol Tweed, Lorraine Tafra, Rubie S Jackson
{"title":"Recurrence Score Testing Does not Appear to Benefit Patients With Grade 1, Progesterone Receptor-Positive Breast Cancers: An Opportunity to Eliminate Overtreatment and Decrease Testing Costs.","authors":"Udai S Sibia,&nbsp;Thomas J Sanders,&nbsp;Charles Mylander,&nbsp;Martin Rosman,&nbsp;Carol Tweed,&nbsp;Lorraine Tafra,&nbsp;Rubie S Jackson","doi":"10.1016/j.hemonc.2021.05.005","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.05.005","url":null,"abstract":"<p><strong>Background: </strong>We previously described a risk prediction model (Anne Arundel Medical Center [AAMC] model) based on pathology which may eliminate the need for recurrence score (RS) testing in select early-stage breast cancers. There is a concern that patients in discordant risk prediction groups (AAMC vs. RS) may be overtreated or undertreated if RS testing were omitted.</p><p><strong>Methods: </strong>We queried the Surveillance, Epidemiology, and End Results (SEER) database for all breast cancer patients between 2004 and 2015. AAMC low-risk was defined as Grade 1 and progesterone receptor-positive (PR + ) tumors, while AAMC high-risk was defined as Grade 3 or estrogen-negative tumors. RS low-risk group was defined as RS < 16 and age ≤ 50 years, or RS ≤ 25 and age > 50 years. RS high-risk group was defined as RS > 25.</p><p><strong>Results: </strong>A total of 71,212 cases were analyzed. Of these, 590 were AAMC low-risk/RS high-risk discordant, while 5,596 were AAMC high-risk/RS low-risk discordant. For AAMC low-risk/RS high-risk discordant, 10-year breast cancer-specific survival (BCSS) did not differ for patients who received adjuvant chemotherapy versus those who did not (93% chemotherapy vs. 99% unknown/no chemotherapy, p = .12). Overall survival (OS) was also comparable (92% chemotherapy vs. 91% unknown/no chemotherapy, p = .42). In the AAMC high-risk/RS low-risk discordant group, 10-year BCSS (92% chemotherapy vs. 96% unknown/no chemotherapy, p = .06) and OS (87% chemotherapy vs. 90% unknown/no chemotherapy, p = .52) did not differ between adjuvant chemotherapy and unknown/no chemotherapy groups.</p><p><strong>Conclusions: </strong>Adjuvant chemotherapy in the AAMC low-risk/RS high-risk and AAMC high-risk/RS low-risk discordant groups did not improve survival. This supports consideration of omission of RS testing in Grade 1, PR + tumors. Patients with Grade 3 tumors do benefit from RS testing.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":" ","pages":"44-51"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.05.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39041176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Prevalence and Distribution of Major β-Thalassemia Mutations and HbE/β-Thalassemia Variant in Nepalese Ethnic Groups. 尼泊尔少数民族β-地中海贫血主要突变和HbE/β-地中海贫血变异的流行和分布
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2021.01.004
Raju Lama, Wardah Yusof, Tilak R Shrestha, Sarifah Hanafi, Matrika Bhattarai, Rosline Hassan, Bin Alwi Zilfalil
{"title":"Prevalence and Distribution of Major β-Thalassemia Mutations and HbE/β-Thalassemia Variant in Nepalese Ethnic Groups.","authors":"Raju Lama,&nbsp;Wardah Yusof,&nbsp;Tilak R Shrestha,&nbsp;Sarifah Hanafi,&nbsp;Matrika Bhattarai,&nbsp;Rosline Hassan,&nbsp;Bin Alwi Zilfalil","doi":"10.1016/j.hemonc.2021.01.004","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.01.004","url":null,"abstract":"<p><strong>Background: </strong>Beta-thalassemia is a genetic disorder that is inherited in an autosomal recessive pattern. This genetic disease leads to a defective beta-globin hemoglobin chain causing partial or complete beta-globin chain synthesis loss. Beta-thalassemia major patients need a continuous blood transfusion and iron chelation to maintain the normal homeostasis of red blood cells (RBCs) and other systems in the body. Patients also require treatment procedures that are costly and tedious, resulting in a serious health burden for developing nations such as Nepal.</p><p><strong>Methods: </strong>A total of 61 individuals clinically diagnosed to have thalassemia were genotyped with multiplex amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Twenty-one major mutations were investigated using allele-specific primers grouped into six different panels.</p><p><strong>Results: </strong>The most common mutations found (23%) were IVS 1-5 (G-C) and Cd 26 (G-A) (HbE), followed by 619 deletion, Cd 8/9 (+G), Cd 16 (-C), Cd 41/42 (-TTCT), IVS 1-1 (G-T), Cd 19 (A-G), and Cd 17 (A-T) at 20%, 12%, 8%, 6%, 4%, 3%, and 1%, respectively.</p><p><strong>Conclusion: </strong>The results of this study revealed that Nepal's mutational profile is comparable to that of its neighboring countries, such as India and Myanmar. This study also showed that thalassemia could be detected across 17 Nepal's ethnic groups, especially those whose ancestors originated from India and Central Asia.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 1","pages":"279-284"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.01.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9248402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Efficacy of Allogeneic Hematopoietic Cell Transplantation in Patients With Chronic Phase CML Resistant or Intolerant to Tyrosine Kinase Inhibitors. 异基因造血细胞移植治疗对酪氨酸激酶抑制剂耐药或不耐受的慢性粒细胞白血病的疗效。
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2021.02.003
Farah Yassine, Tea Reljic, Muhamad Alhaj Moustafa, Madiha Iqbal, Hemant S Murthy, Ambuj Kumar, Mohamed A Kharfan-Dabaja
{"title":"Efficacy of Allogeneic Hematopoietic Cell Transplantation in Patients With Chronic Phase CML Resistant or Intolerant to Tyrosine Kinase Inhibitors.","authors":"Farah Yassine,&nbsp;Tea Reljic,&nbsp;Muhamad Alhaj Moustafa,&nbsp;Madiha Iqbal,&nbsp;Hemant S Murthy,&nbsp;Ambuj Kumar,&nbsp;Mohamed A Kharfan-Dabaja","doi":"10.1016/j.hemonc.2021.02.003","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.02.003","url":null,"abstract":"<p><p>Approximately 15-20% of chronic myeloid leukemia (CML) patients fail tyrosine kinase inhibitor (TKI) therapy secondary to resistance or intolerance. In the pre-TKI era, front-line allogeneic hematopoietic cell transplantation (allo- HCT) represented the standard approach for patients with chronic phase-CML (CP-CML) who were deemed fit to tolerate the procedure and had a human leukocyte antigen compatible donor available. Currently, CP-CML patients are eligible for allo-HCT only if they fail more than one TKI and/or are intolerant to the drug. We performed a systematic review/meta-analysis of the available literature to assess the evidence regarding allo-HCT efficacy in CP-CML patients. Data from eligible studies were extracted in relation to benefits (overall survival [OS], progression-free survival, disease-free survival [DFS], complete remission [CR], and molecular response [MR]) and harms (nonrelapse mortality [NRM], relapse, and acute and chronic graft-versus-host disease), and stratified by age into adult and pediatric groups. For adult allo-HCT recipients, the pooled OS, DFS, CR and, MR were 84% [95% confidence interval (CI) 59-99%], 66% (95% CI 59-73%), 56% (95% CI 30-80%), and 88% (95% CI 62-98%), respectively. Pooled NRM and relapse were 20% (95% CI 15-26%) and 19% (95% CI 10-28%), respectively. For the pediatric group, the OS rate was reported in one study and was 91% (95% CI 72-99%). Our results suggest that allo-HCT is an effective treatment for TKI-resistant or TKI-intolerant CP-CML. Post-transplant strategies are still needed to further mitigate the risk of relapse.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":" ","pages":"36-43"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.02.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25534709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Use of Thrombopoietin Receptor Agonists in Pregnancy: A Review of the Literature. 妊娠期血小板生成素受体激动剂的应用:文献综述。
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2021.05.004
Jude Howaidi, Abdullah M AlRajhi, Ali Howaidi, Fouad H AlNajjar, Imran K Tailor
{"title":"Use of Thrombopoietin Receptor Agonists in Pregnancy: A Review of the Literature.","authors":"Jude Howaidi,&nbsp;Abdullah M AlRajhi,&nbsp;Ali Howaidi,&nbsp;Fouad H AlNajjar,&nbsp;Imran K Tailor","doi":"10.1016/j.hemonc.2021.05.004","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.05.004","url":null,"abstract":"<p><p>The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a shift in treatment modalities. Eltrombopag and romiplostim have proven to be effective in the management of ITP through clinical studies, but their safety in pregnancy remains uncertain. The purpose of the study is to review the literature to evaluate the safety of TPO-RAs in pregnant women. Ten case reports and a cohort study pertaining to the use of TPO-RAs in pregnancy were obtained. According to the reported cases and prospective study, the use of eltrombopag and romiplostim appears to be relatively safe in the first, second, and third trimesters, as there were no reported congenital malformations. Low fetal birth weight has been observed following the administration of eltrombopag during the second trimester, whereas preterm birth has occurred following the administration of eltrombopag in the third trimester. Eltrombopag and romiplostim seem relatively safe. Further studies are necessary to clarify their safety during pregnancy.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":" ","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.05.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39259154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Philadelphia Chromosome-Positive T-cell Acute Lymphoblastic Leukemia: A Case Report and Review of the Literature. 费城染色体阳性t细胞急性淋巴母细胞白血病1例报告及文献复习。
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2020.02.004
Ahmad Alshomar, Riad El Fakih
{"title":"Philadelphia Chromosome-Positive T-cell Acute Lymphoblastic Leukemia: A Case Report and Review of the Literature.","authors":"Ahmad Alshomar,&nbsp;Riad El Fakih","doi":"10.1016/j.hemonc.2020.02.004","DOIUrl":"https://doi.org/10.1016/j.hemonc.2020.02.004","url":null,"abstract":"","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 1","pages":"59-62"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.02.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10615679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Ofatumumab for Post-Transplant Lymphoproliferative Disorder. Ofatumumab治疗移植后淋巴增生性疾病。
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2020.04.004
Madhav Seshadri, Genevieve M Crane, Usama Gergis
{"title":"Ofatumumab for Post-Transplant Lymphoproliferative Disorder.","authors":"Madhav Seshadri,&nbsp;Genevieve M Crane,&nbsp;Usama Gergis","doi":"10.1016/j.hemonc.2020.04.004","DOIUrl":"https://doi.org/10.1016/j.hemonc.2020.04.004","url":null,"abstract":"<p><p>Posttransplant lymphoproliferative disorder (PTLD) includes a range of abnormal lymphoid proliferation following solid organ or allogeneic hematopoietic stem cell transplantation (HSCT), often associated with Epstein-Barr virus (EBV) infection. Treatment generally incudes rituximab, a chimeric monoclonal antibody directed against CD20. Here we present a 56-year-old woman with EBV-associated PTLD following allogeneic HSCT who was intolerant of rituximab. The patient was instead treated with ofatumumab, a fully human monoclonal antibody directed against CD20, with significant response in EBV viral load and lymphadenopathy. Ofatumumab could represent an important treatment option for patients unable to tolerate rituximab.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":" ","pages":"68-73"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.04.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37939620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Predictors of Outcomes of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. 异基因造血干细胞移植后治疗相关性急性髓系白血病预后的预测因素。
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2021.03.003
Ram Vasudevan Nampoothiri, Arjun Datt Law, Wilson Lam, Carol Chen, Zeyad Al-Shaibani, David Loach, Fotios V Michelis, Dennis Dong Hwan Kim, Jonas Mattsson, Rajat Kumar, Jeffrey Howard Lipton, Auro Viswabandya
{"title":"Predictors of Outcomes of Therapy-Related Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.","authors":"Ram Vasudevan Nampoothiri,&nbsp;Arjun Datt Law,&nbsp;Wilson Lam,&nbsp;Carol Chen,&nbsp;Zeyad Al-Shaibani,&nbsp;David Loach,&nbsp;Fotios V Michelis,&nbsp;Dennis Dong Hwan Kim,&nbsp;Jonas Mattsson,&nbsp;Rajat Kumar,&nbsp;Jeffrey Howard Lipton,&nbsp;Auro Viswabandya","doi":"10.1016/j.hemonc.2021.03.003","DOIUrl":"https://doi.org/10.1016/j.hemonc.2021.03.003","url":null,"abstract":"<p><strong>Background/objective: </strong>Existing literature on allogeneic hematopoietic stem cell transplantation (allo-HSCT) in therapy-related acute myeloid leukemia (t-AML) is confounded by the inclusion of patients with secondary AML and t-MDS. We aim to report our 20-year experience of HSCT in t-AML.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with t-AML who underwent HSCT. Patients were analyzed for prior malignancy, therapy, time to diagnosis of t-AML, transplant details, relapse-free survival (RFS), overall survival (OS), and predictors of outcomes.</p><p><strong>Results: </strong>In total, 68 patients (59.9% female; median age, 56.5 years) underwent HSCT. Acute and chronic graft-versus-host disease (GVHD) occurred in 39 (57.4%) and 23 (33.8%) patients, respectively. Cumulative incidence of relapse, nonrelapse mortality, RFS, and OS at 2 years were 17.9%, 34.5%, 47.6%, and 49.3%, respectively. Significant predictors of reduced OS were presence of 11q23 rearrangement (hazard ratio [HR], 3.24), using induction regimens other than FLAGI-da or 7 + 3 (HR, 3.65), haploidentical donors (HR, 3.48), Eastern Cooperative Oncology Group performance status 2 or higher (HR, 5.83), and using cyclosporine A-methotrexate as GVHD prophylaxis (HR, 2.41). A significant decrement in survival was seen with an increasing number of any of these prognostic factors.</p><p><strong>Conclusion: </strong>Outcomes of t-AML are satisfactory after allo-HSCT. Patients with t-AML with good-risk karyotypes, good performance status, having HLA-matched donors, and receiving intensive induction regimens have better outcomes after HSCT.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":" ","pages":"27-35"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.03.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25523628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Update on the Availability of Essential Medications for Pediatric Cancer Patients in Armenia: How to Solve the Problem? 亚美尼亚儿童癌症患者获得基本药物的最新情况:如何解决这个问题?
Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-03-01 DOI: 10.1016/j.hemonc.2020.05.009
Saten Hovhannisyan, Julieta Hoveyan, Tigran Aghabekyan, Gevorg Tamamyan
{"title":"Update on the Availability of Essential Medications for Pediatric Cancer Patients in Armenia: How to Solve the Problem?","authors":"Saten Hovhannisyan,&nbsp;Julieta Hoveyan,&nbsp;Tigran Aghabekyan,&nbsp;Gevorg Tamamyan","doi":"10.1016/j.hemonc.2020.05.009","DOIUrl":"https://doi.org/10.1016/j.hemonc.2020.05.009","url":null,"abstract":"","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 1","pages":"74-76"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.05.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9183756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信